Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate

Baumert, Thomas F.; Vergalla, John; Satoi, Jujin; Thomson, Michael M.; Lechmann, Martin; Herion, David; Greenberg, Harry B.; Ito, Susumu; Liang, T. Jake

doi:10.1016/s0016-5085(99)70290-8

Cited by 111 publications

(129 citation statements)

References 33 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…HCV-LPs were partially purified by sucrose gradient centrifugation as described (14). Purification of E1͞E2 from vvHCV.S-infected BHK-21 cells and of core from a bacterial expression system has been described (14,15).…”

Section: Methodsmentioning

confidence: 99%

“…We have reported the synthesis of HCV-like particles (HCV-LPs) by using a recombinant baculovirus that contains the cDNA of the HCV structural proteins (core͞E1͞E2). These HCV-LPs have biophysical, ultrastructural, and antigenic properties similar to those of the putative virions (14,15). We recently reported that BALB͞c mice immunized with HCV-LPs generated strong and broad humoral and cellular immune responses against HCV structural proteins (15,16).…”

mentioning

confidence: 99%

“…These HCV-LPs have biophysical, ultrastructural, and antigenic properties similar to those of the putative virions (14,15). We recently reported that BALB͞c mice immunized with HCV-LPs generated strong and broad humoral and cellular immune responses against HCV structural proteins (15,16). Furthermore, HCV-LPs without p7 elicited a Th1-biased cellular immunity in BALB͞c mice (16).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

Murata

Lechmann

Qiao

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

149

122

View full text Add to dashboard Cite

We have recently demonstrated that immunization with hepatitis C virus-like particles (HCV-LPs) generated in insect cells can elicit both humoral and cellular immune responses in BALB͞c mice. Here, we evaluate the immunogenicity of HCV-LPs in HLA2.1 transgenic (AAD) mice in comparison to DNA immunization. HCV-LP immunization elicited a significantly stronger humoral immune response than DNA immunization. HCV-LP-immunized mice also developed stronger HCV-specific cellular immune responses than DNA-immunized mice as determined by using quantitative enzyme-linked immunospot (ELISpot) assay and intracellular cytokine staining. In BALB͞c mice, immunization with HCV-LPs resulted in a >5 log10 reduction in vaccinia titer when challenged with a recombinant vaccinia expressing the HCV structural proteins (vvHCV.S), as compared to 1 log 10 decrease in DNA immunization. In HLA2.1 transgenic mice, a 1-2 log10 reduction resulted from HCV-LP immunization, whereas no reduction was seen from DNA immunization. Adoptive transfer of lymphocytes from HCV-LP-immunized mice to naive mice provided protection against vvHCV.S challenge, and this transferred immunity can be abrogated by either CD4 or CD8 depletion. Our results suggest that HCV-LPs can induce humoral and cellular immune responses that are protective in a surrogate HCV challenge model and that a strong cellular immunity provided by both CD4 and CD8 effector lymphocytes may be important for protection from HCV infection.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

Murata

Lechmann

Qiao

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

149

122

View full text Add to dashboard Cite

show abstract

“…E1 and E2 proteins were expressed in vvHCV.S-infected BSC-1 cells and purified by lectin column chromatography (30). HCV core protein (amino acids 1-115) was purchased from Mikrogen (Neuried, Germany).…”

Section: Methodsmentioning

confidence: 99%

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

Elmowalid

Qiao

Jeong

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

155

114

View full text Add to dashboard Cite

Recombinant hepatitis C virus (HCV)-like particles (HCV-LPs) containing HCV structural proteins (core, E1, and E2) produced in insect cells resemble the putative HCV virions and are capable of inducing strong and broad humoral and cellular immune responses in mice and baboons. Here, we present evidence on the immunogenicity and induction of protective immunity by HCV-LPs in chimpanzees. Chimpanzees (two in each group), were immunized with HCV-LPs or HCV-LPs plus AS01B adjuvant. After immunizations, all animals developed an HCV-specific immune response including IFN-␥ ؉ , IL-2 ؉ , CD4 ؉ , and CD8 ؉ T cell and proliferative lymphocyte responses against core, E1, and E2. Upon challenge with an infectious HCV inoculum, one chimpanzee developed transient viremia with low HCV RNA titers (10 3 to 10 4 copies per ml) in the third and fourth weeks after the challenge. The three other chimpanzees became infected with higher levels of viremia (10 4 to 10 5 copies per ml), but their viral levels became unquantifiable (<10 3 copies per ml) 10 weeks after the challenge. After the HCV challenge, all four chimpanzees demonstrated a significant increase in peripheral and intrahepatic T cell and proliferative responses against the HCV structural proteins. These T cell responses coincided with the fall in HCV RNA levels. Four naïve chimpanzees were infected with the same HCV inoculum, and three developed persistent infection with higher viremia in the range of 10 5 to 10 6 copies per ml. Our study suggests that HCV-LP immunization induces HCV-specific cellular immune responses that can control HCV challenge in the chimpanzee model. envelope proteins ͉ prevention ͉ protective immunity ͉ vaccine ͉ viral clearance H epatitis C virus (HCV) is a major public health problem.Approximately 170 million people are infected by the virus worldwide (1, 2). HCV causes a high rate of chronic infection, which can lead to complications of chronic liver disease such as liver cirrhosis and hepatocellular carcinoma. The efficacy of therapy for chronically infected patients is less than satisfactory. Development of an effective vaccine may hold the key to controlling HCV infection. HCV displays high genetic and antigenic diversities, with at least six different genotypes and diverse quasispecies within infected individuals (1, 2). In addition to this inherent problem, the lack of convenient and robust tissue culture systems and small animal models further hampers the effort to develop an effective HCV vaccine (3). The use of recombinant HCV envelope proteins as a vaccine candidate has been met with variable success. High titers of anti-E1/E2 antibodies could be induced and possibly resulted in lower propensity to chronicity upon HCV challenge (3-5). Recently, a combined modality of plasmid DNA and adenoviral vector to deliver HCV structural and nonstructural antigens induced a strong HCV-specific cell-mediated immunity in chimpanzees and resulted in attenuated HCV infection after challenge (6). However, in this study, no obvious difference was observe...

show abstract

“…Although putative HCV-LPs were observed by EM in large ER cisternae in the insect cells infected with these recombinant baculoviruses, they were not secreted and could only be purified by cell lysis and detergent treatment. As for the VLPs of papillomaviruses and retroviruses, which are currently being evaluated for vaccine strategies (Stanley et al, 2002;Young et al, 2003), the HCV-LPs produced by insect cells induce humoral and cellular immune responses and are therefore promising as candidate vaccines against HCV (Baumert et al, 1999;Lechman et al, 2001;Murata et al, 2003). The HCV-LPs obtained with the baculovirus expression system have also been used to investigate binding to host-cell plasma membranes and for studies of HCV receptors (Wellnitz et al, 2002;Triyatni et al, 2002;Saunier et al, 2003).…”

Section: The Virus-like Particle (Vlp) Modelmentioning

confidence: 99%

Hepatitis C virus ultrastructure and morphogenesis

Roingeard

Hourioux

Blanchard

et al. 2004

Biology of the Cell

View full text Add to dashboard Cite

Details of the ultrastructure of hepatitis C virus (HCV) virion remain unclear because it has proved extremely difficult to visualise virus particles from infected serum and tissues directly. In addition, although much is known about the viral genome, first cloned in 1989, little is known about HCV morphogenesis, due to the lack of an efficient in vitro culture system for HCV propagation. Virus-like particles (VLPs) obtained by expressing genes encoding the HCV structural proteins in mammalian cells can be used as an alternative model for studying HCV morphogenesis. In particular, this HCV-LP model has made it possible to demonstrate that HCV budding occurs at the ER membrane and that the core protein drives this process. The HCV-LP model opens up new possibilities for the investigation of viral morphogenesis and virus-host cell interactions, which may make it possible to establish the long-awaited in vitro culture system for HCV.

show abstract

Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate

Cited by 111 publications

References 33 publications

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

Hepatitis C virus ultrastructure and morphogenesis

Contact Info

Product

Resources

About